Preparation of finasteride capsules-loaded drug nanoparticles: Formulation, optimization, in vitro, and pharmacokinetic evaluation

International Journal of Nanomedicine

Volumn 11, Issue , 2016, Pages 515-527

  Ahmed, Tarek A ^a,b  

^a KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^b Al Azhar University   (Egypt)

Author keywords

Crystal growth; Finasteride; Nanoparticles; Optimization; Pharmacokinetic; Solvent evaporation

Indexed keywords

FINASTERIDE; NANOPARTICLE; MICROCAPSULE;

ANIMAL EXPERIMENT; ARTICLE; CONTROLLED STUDY; CRYSTALLIZATION; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG DOSAGE FORM; DRUG ELIMINATION; DRUG FORMULATION; DRUG SOLUBILITY; DRUG STABILITY; DRUG SYNTHESIS; FREEZE DRYING; IN VITRO STUDY; MALE; NONHUMAN; PARTICLE SIZE; PHARMACOKINETIC PARAMETERS; PHYSICAL CHEMISTRY; PROCESS OPTIMIZATION; SINGLE DRUG DOSE; SUSPENSION; TRANSMISSION ELECTRON MICROSCOPY; X RAY POWDER DIFFRACTION; ANIMAL; BIOAVAILABILITY; CHEMISTRY; MEDICINAL CHEMISTRY; MICROCAPSULE; PROCEDURES; RABBITS AND HARES; SOLUBILITY; X RAY DIFFRACTION;

ANIMALS; BIOLOGICAL AVAILABILITY; CAPSULES; CHEMISTRY, PHARMACEUTICAL; CRYSTALLIZATION; FINASTERIDE; FREEZE DRYING; MALE; MICROSCOPY, ELECTRON, TRANSMISSION; NANOPARTICLES; PARTICLE SIZE; RABBITS; SOLUBILITY; X-RAY DIFFRACTION;

EID: 84957574762     PISSN: 11769114     EISSN: 11782013     Source Type: Journal    
DOI: 10.2147/IJN.S98080     Document Type: Article

References (40)

1. Khadka P, Ro J, Kim H, et al. Pharmaceutical particle technologies: an approach to improve drug solubility, dissolution and bioavailability. Asian J Pharm Sci. 2014;9(6):304–316. doi:10.1016/j.ajps.2014.05.005.
2. Badr-Eldin SM, Ahmed TA, Ismail HR. Aripiprazole-cyclodextrin binary systems for dissolution enhancement: effect of preparation technique, cyclodextrin type and molar ratio. Iran J Basic Med Sci. 2013;16(12):1223–1231.
3. Shid RL, Dhole SN, Kulkarni N, Shid SL. Nanosuspension: a review. Int J Pharm Sci Rev Res. 2013;22(1):98–106.
4. Kumar GP, Krishna KG. Nanosuspensions: the solution to deliver hydrophobic drugs. Int J Drug Deliv. 2011;3(4):546–557. doi:10.5138/385.
5. Ahmed TA. Preparation of transfersomes encapsulating sildenafil aimed for transdermal drug delivery: Plackett–Burman design and characterization. J Liposome Res. 2015;25(1):1–10. doi:10.3109/08982104.2014.950276.
6. El-Say KM, Ahmed TA, Badr-Eldin SM, Fahmy U, Aldawsari H, Ahmed OAA. Enhanced permeation parameters of optimized nanostructured simvastatin transdermal films: ex vivo and in vivo evaluation. Pharm Dev Technol. 2015;20(8):919–926. doi:10.3109/10837450.2014.938859.
7. Ahmed OAA, Badr-Eldin SM, Tawfik MK, Ahmed TA, El-Say KM, Badr JM. Design and optimization of self-nanoemulsifying delivery system to enhance quercetin hepatoprotective activity in paracetamol-induced hepatotoxicity. J Pharm Sci. 2014;103(2):602–612. doi:10.1002/jps.23834.
8. Al-Subaie MM, Hosny KM, Mohamed El-Say K, Ahmed TA, Aljaeid BM. Utilization of nanotechnology to enhance percutaneous absorption of acyclovir in the treatment of herpes simplex viral infections. Int J Nanomedicine. 2015;10:3973–3985. doi:10.2147/IJN.S83962.
9. Sutradhar KB, Khatun S, Luna IP. Increasing possibilities of nanosuspension. J Nanotechnol. 2013;2013:1–12. doi:10.1155/2013/346581.
10. Li W, Yang Y, Tian Y, et al. Preparation and in vitro/in vivo evaluation of revaprazan hydrochloride nanosuspension. Int J Pharm. 2011;408(1–2):157–162. doi:10.1016/j.ijpharm.2011.01.059.
11. Jacobs C, Kayser O, Müller RH. Production and characterisation of mucoadhesive nanosuspensions for the formulation of bupravaquone. Int J Pharm. 2001;214(1–2):3–7.
12. Patravale VB, Date AA, Kulkarni RM. Nanosuspensions: a promising drug delivery strategy. J Pharm Pharmacol. 2004;56(7):827–840. doi:10.1211/0022357023691.
13. Keck CM, Müller RH. Drug nanocrystals of poorly soluble drugs produced by high pressure homogenisation. Eur J Pharm Biopharm. 2006;62(1):3–16. doi:10.1016/j.ejpb.2005.05.009.
14. Faller B, Farley D, Nick H. Finasteride: a slow-binding 5 alpha-reductase inhibitor. Biochemistry. 1993;32(21):5705–5710.
15. Steiner JF. Clinical pharmacokinetics and pharmacodynamics of finasteride. Clin Pharmacokinet. 1996;30(1):16–27.
16. Prahalada SR, Keenan KP, Hertzog PR, et al. Qualitative and quantitative evaluation of prostatic histomorphology in rats following chronic treatment with finasteride, a 5-alpha reductase inhibitor. Urology. 1994;43(5):680–685.
17. Wang Y, Liu Z, Zhang D, et al. Development and in vitro evaluation of deacety mycoepoxydiene nanosuspension. Colloids Surf B Biointerfaces. 2011;83(2):189–197. doi:10.1016/j.colsurfb.2010.10.029.
18. Ibrahim HM, Ahmed TA, Hussain MD, et al. Development of meloxicam in situ implant formulation by quality by design principle. Drug Dev Ind Pharm. 2013;9045:1–8. doi:10.3109/03639045.2012.746360.
19. US Food and Drug Administration. Bioequivalence Studies with Pharmacokinetic Endpoints for Drugs Submitted Under an ANDA. US Department of Health and Human Services: Rockville, MD, USA; 2013. Available from: http://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm377465.pdf.
20. Anutra K, Kumsorn B, Rojanasthien N. Bioequivalence study of generic finasteride in healthy male volunteers. Chiang Mai Med Bull. 2003;42(4):131–137.
21. Wang Y, Zheng Y, Zhang L, Wang Q, Zhang D. Stability of nanosuspensions in drug delivery. J Control Release. 2013;172(3):1126–1141. doi:10.1016/j.jconrel.2013.08.006.
22. Sahu BP, Das MK. Optimization of felodipine nanosuspensions using full factorial design. Int J PharmTech Res. 2013;5(2):553–561.
23. El-Badry M, Fetih G, Salem-Bekhit MM, Shakeel F. Formulation and evaluation of nanosuspension of albendazole for dissolution enhancement. Nanosci Nanotechnol Lett. 2013;5(9):1024–1029. doi:10.1166/nnl.2013.1645.
24. Pandya VM, Patel JK, Patel DJ. Formulation and optimization of nanosuspensions for enhancing simvastatin dissolution using central composite design. Dissolut Technol. 2011;18:40–45.
25. Esfandi E, Ramezani V, Vatanara A, Rouholamini Najafabadi A, Hadipour Moghaddam SP. Clarithromycin dissolution enhancement by preparation of aqueous nanosuspensions using sonoprecipitation technique. Iran J Pharm Res. 2014;13(3):809–818.
26. Mishra B, Arya N, Tiwari S. Investigation of formulation variables affecting the properties of lamotrigine nanosuspension using fractional factorial design. Daru. 2010;18(1):1–8.
27. Wiśniewska M. The temperature effect on electrokinetic properties of the silica-polyvinyl alcohol (PVA) system. Colloid Polym Sci. 2011;289(3):341–344. doi:10.1007/s00396-010-2341-4.
28. Quan P, Shi K, Piao H, et al. A novel surface modified nitrendipine nanocrystals with enhancement of bioavailability and stability. Int J Pharm. 2012;430(1–2):366–371. doi:10.1016/j.ijpharm.2012.04.025.
29. Thakkar HP, Patel BV, Thakkar SP. Development and characterization of nanosuspensions of olmesartan medoxomil for bioavailability enhancement. J Pharm Bioallied Sci. 2011;3(3):426–434. doi:10.4103/0975-7406.84459.
30. Ito T, Sun L, Bevan MA, Crooks RM. Comparison of nanoparticle size and electrophoretic mobility measurements using a carbon-nanotube-based coulter counter, dynamic light scattering, transmission electron microscopy, and phase analysis light scattering. Langmuir. 2004;20(16):6940–6945. doi:10.1021/la049524t.
31. Brown ME. Introduction to Thermal Analysis: Techniques and Applications. Berlin, Germany: Springer Science & Business Media; 2001.
32. Nagalaxmi V, Mahipal Reddy L, Manikanta Kumar A, Manjunath Shetty KS. Formulation and evaluation of controlled release matrix tablets of finasteride. Int J Pharm Dev Technol. 2014;4(1):63–70.
33. Kurakula M, Ahmed TA. Co-delivery of atorvastatin nanocrystals in PLGA based in situ gel for anti-hyperlipidemic efficacy. Curr Drug Deliv. 2016;13:1–11.
34. Gao Y, Qian S, Zhang J. Physicochemical and pharmacokinetic characterization of a spray-dried cefpodoxime proxetil nanosuspension. Chem Pharm Bull (Tokyo). 2010;58(7):912–917.
35. Lee J. Drug nano-and microparticles processed into solid dosage forms: physical properties. J Pharm Sci. 2003;92(10):2057–2068. doi:10.1002/jps.10471.
36. Sahu BP, Das MK. Nanosuspension for enhancement of oral bioavailability of felodipine. Appl Nanosci. 2013;4(2):189–197. doi:10.1007/s13204-012-0188-3.
37. Maria O, Santos M, Laura A, Santos A, Pereira GR, Bonfilio R. A dissolution test for finasteride in immediate-release capsules. Dissolution Technol. 2013;20(3):25–33.
38. El-Say KM, El-Helw A-RM, Ahmed OA, et al. Statistical optimization of controlled release microspheres containing cetirizine hydrochloride as a model for water soluble drugs. Pharm Dev Technol. 2015;20(6):738–746. doi:10.3109/10837450.2014.920353.
39. Ahmed TA, El-Say KM, Mahmoud MF, Samy AM, Badawi AA. Miconazole nitrate oral disintegrating tablets: in vivo performance and stability study. AAPS PharmSciTech. 2012;13(3):760–771. doi:10.1208/s12249-012-9798-z.
40. Hui Y, Huang NH, Ebbert L, et al. Pharmacokinetic comparisons of tail-bleeding with cannula-or retro-orbital bleeding techniques in rats using six marketed drugs. J Pharmacol Toxicol Methods. 56(2):256–264. doi:10.1016/j.vascn.2007.05.006.